Résumé :
|
[BDSP. Notice produite par INIST R0xAlfqv. Diffusion soumise à autorisation]. After initiation of a treatment for human immunodeficiency virus type 1 infection containing a protease inhibitor, immune restoration associated with increases in CD4-positive (CD4+) T lymphocyte count may be delayed. In a sample of patients who had been prescribed protease inhibitors for the first time, the authors tested to see whether there was a minimal duration of CD4+cell count increase before the increase had an impact on the occurrence of opportunistic infections. The evolution (difference between time t and baseline) of CD4+cell count was modeled using a mixed effects linear model. Changes in CD4+count estimated by this model were then included as time-dependent covariates in a proportional hazards model. Finally, the authors tested for the existence of a CD4+change x time interaction. The authors used a sample of 553 French patients first prescribed protease inhibitors in 1996 and followed for a median of 16 months. During the first 120 days, there was no association between CD4+change and the rate of opportunistic infections. After 120 days, each 50-cell/mm3 increase in CD4+count was associated with a 60% (95% confidence interval : 45,72) reduction in the incidence of opportunistic infections. These results, based on modeling of CD4+cell response, at least indirectly reinforce the concept of a delayed but possible immune recovery with the use of protease inhibitors. (...)
|